The Pharmacy Times® Dermatology resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
Trending News Today: Early Levels of Ustekinumab May Determine Patient Response
Top news of the day across the health care landscape.
Dupilumab Shows Positive Results in Children with Severe Atopic Dermatitis
A phase 3 trial evaluated dupilumab (Dupixent, Regeneron and Sanofi) in children from 6 to 11 years of age with severe atopic dermatitis.
Trending News Today: Patients with Psoriasis May Be at Elevated Risk of Cancer
Top news of the day from across the health care landscape.
Patients Frequently Use Complementary, Alternative Medicines for Psoriasis When Other Therapies Fail
Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.
Certain Biologic Treatments May Be Safer for Patients with Psoriasis
The study focused on the comparative risk of infection across 7 systemic biologics.
Trending News Today: Psoriasis Associated with Higher Risk of Mental Health Disorders
Top news of the day from across the health care landscape.
Trending News Today: Atopic Dermatitis Drug Improves Skin Clearing in Late-Stage Study
Top news of the day from across the health care landscape.
Study Compares Quality of Life Improvements in Secukinumab Versus Ustekinumab
A head-to-head trial evaluated quality of life improvements in patients with moderate-to-severe psoriasis treated with secukinumab (Cosentyx) or ustekinumab (Stelara).
Expanded Dupilumab Indication Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
FDA OKs Dupilumab Indication for Adolescents with Atopic Dermatitis
With this approval, dupilumab (Dupixent) offers a biologic therapy option for patients 12 to 17 years of age who have moderate-to-severe atopic dermatitis.
What is the Most Cost-Effective Plaque Psoriasis Treatment?
Approximately 1.7 million insured US patients are burdened with moderate to severe plaque psoriasis.
Biologic Drug Shows Promise Treating Moderate-to-Severe Psoriasis
Tildrakizumab was approved by the FDA as a subcutaneous therapy for patients with moderate-to-severe psoriasis.
+ Load More